Advances In Diabetes Treatment 2005

ADVANCES IN DIABETES TREATMENT 2005
Insulin Resistance, Novel Delivery Methods and Anti-Obesity Therapies
23rd and 24th March 2005, Workshop 22nd March 2005
Marriott Kensington Hotel, London

**PDF brochure available - order yours today**
-full agenda below-

QUOTES FROM LAST YEAR'S DELEGATES;
'Very professional. Well organised!' Serono - 2004
'Very stimulating conference' Medtronic- 2004
'Very informative scientific discussions' Aventis 2004
'Excellent programme' Altea- 2004

KEY THEMES
*How to overcome the challenges in developing
novel anti-diabetic therapies
*New approaches to improve clinical development
for your organization
*Learn from the best practice case studies such as:
Sanofi-Aventis, Eli Lilly, Bayer, Pfizer and Roche
*How to overcome the growing concern of insulin
resistance: Ways to tackle and understand the
mechanism of action behind resistance
*Pinpoint where opportunities lie: Promising
partnership compounds currently in clinical trials
*Advancements in medical technologies
*Explore new avenues in the market: analyse
complications associated with diabetes

KEY SPEAKERS
*Dr. Richard Carr, Vice President, New Antidiabetic Agents, Novo Nordisk
*Dr. Andreas Festa, Medical Advisor, Eli Lilly
*Dr. Manfred Ganz, Diabetologist (DDG), Specialist Internal Medicine, Roche
Diagnostics
*Dr. H. James Harwood, Principle Research Investigator, Cardiovascular &
Metabolic Diseases, Pfizer
*Professor Günter Müller, Section Head Biochemistry,TD Metabolism,
Sanofi-Aventis
*Dr. Jacques Mizrahi, Global Therapy Area Head, Vascular and Metabolic
Diseases, Roche
Professor Chris Price, VP, Outcomes Research, Bayer Healthcare & President,
Association of Clinical Biochemists
*Dr. Nandan Koppiker, Director, Pfizer Global R&D
*Dr. Gerald Berstein, Vice President, Medical Affairs, Generex Biotechnology
*Dr. Ehud Arbit, Vice President, Medical Research, Emisphere Technologies
*Dr. David Maggs, Senior Director, Medical Affairs, Amylin
*Dr. Wendy MacFarlane, Lecturer, University of Newcastle-upon-Tyne
*Professor Ross Lawrenson, Head of School, University of Surrey, &
Non-Executive Director, Sussex Health Authority

PRE-CONFERENCE INTERACTIVE WORKSHOP 22nd March 2005
Strategies for Pricing and Market Access of New Diabetes Drugs
Led by: Klaus Hilleke, Director, Simon-Kucher & Partners
*P&R environment for diabetes products in 2005
*Critical success factors for market access in diabetes
*Examples of recent learning from new diabetes launches
*What it means for R&D

WHO SHOULD ATTEND? (JOB TITLES);
* Senior Director, Endocrinology & Metabolism
* Vice President, Cardiovascular & Metabolic Diseases
* Vice President, Diabetes & Obesity, Clinical R&D
* Vice President, New Antidiabetic Agents
* Medical Director, Metabolic Disease Research
* Head, Advanced Diabetes Systems
* Project Leader, CVGI Discovery
* Principle Investigator, Department of Metabolic Research
* Chief Scientific Officer
* Director, New Products Global Marketing
* Director, Licensing and Partnership


---------------------
DELEGATE REGISTRATION
---------------------

Places at this event are strictly limited so BOOK YOUR PLACE NOW.
To make a booking on this event, please contact me via phone or email. Book
early to secure a place.

- PRICING -

Attend the:
Two Day conference with interactive workshop - ONLY GBP1600 plus VAT
Two Day conference - ONLY GBP1299 plus VAT
Workshop only - ONLY GBP650 plus VAT

- BOOKINGS -

Booking is easy, simply contact Joe Stone on:

Telephone: +44 (0)20 8767 6711
Fax: +44 (0)20 8767 5001
Terms and conditions apply - see below
Email: mailto:joe.stone@visiongain.com

To book your place at simply
give me a quick ring or email me stating whether you require a single place
or a group booking.
I look forward to hearing from you soon.

Regards,

Joe Stone
Account Manager
Visiongain b2b Conferences
Tel: +44 (0) 20 8767 6711
mailto:joe.stone@visiongain.com



PROMOTIONAL OPPORTUNITIES
2nd Annual Advances in Diabetes Treatment 2005 will provide senior
executives with the latest news, analysis and developments in this
key area, with massive exposure to companies involved in this event.
Opportunities available to you at this event are:
* Exhibition stand sponsorship
* Insert into delegate pack
* Host a cocktail reception
* Host a delegate dinner
* Branded bags, pens & gifts
Learn from leading professionals representing some of the most
innovative companies in the diabetes therapies industry today: Novo
Nordisk, Sanofi-Aventis, Roche, Eli Lilly, Pfizer, Bayer, Emisphere and
Generex
If you would like more information on the range of sponsorship or
exhibition possibilities, please contact:
Andrew Oliver
Tel:+44 (0)208 7676711
Email: [Only registered users see links. ]


=========================
AGENDA
=========================

PRE-CONFERENCE INTERACTIVE WORKSHOP
Strategies for Pricing and Market Access of New Diabetes Drugs
Tuesday 22nd March 2005

Led by: Klaus Hilleke, Director, Simon-Kucher & Partners
Workshop schedule
This workshop will give you the opportunity to engage in
knowledge-sharing with fellow professionals, which can result in
brainstorming and creating ideas which you can use back in your
own organisation. You can gain a greater understanding of the
pricing of diabetes drugs, have detailed discussions about market
access and new ventures.

Main topics of discussion:
* P&R environment for diabetes products in 2005
* Critical success factors for market access in diabetes
* Examples of recent learning from new diabetes drug
launches
* What it means for R&D


DAY ONE WEDNESDAY 23RD MARCH 2005

Conference Chair Day One
Dr. Richard Carr
Vice President, New Antidiabetic Agents
Novo Nordisk

09:00 Registration and coffee

09:30 Opening remarks from the chair

GLOBAL MARKET TRENDS IN DIABETES

09:40 Global trends in diabetes treatments
* Current unmet needs - what needs to be improved?
* Examine the effectiveness of current and emerging
therapies
* How promising are the novel therapeutic targets?
- Evaluate clinical values and detect adverse effects
* How are diabetes treatments evolving in world markets?
- The growing concern of insulin resistance
Professor Ross Lawrenson
Head of School & Professor of Primary Healthcare
University of Surrey
Non-Executive Director,
Sussex Health Authority

10:20 Implementing preventive measures in type 2
diabetes
* Problematic issues with the prevalence of undiagnosed
diabetes - a growing global concern
* Analyse current economic issues & explore opportunities
in unmet needs - identify paths to enter the market
* Explore methods to enhance early detection
- Effective diabetes management
- Blood glucose monitoring and early screening systems
* Outlook: Future developments in glucose monitoring
Dr. Manfred Ganz
Diabetologist (DDG), Specialist Internal Medicine
Roche Diagnostics

11:00 Morning Coffee

11:20 Novel GSK3 inhibitors - potential therapeutics for
treatment of Type 2 diabetes
* GSK 3 - potential therapeutic target for Diabetes
* Examine structure-based drug design and structure-activity
relationships - what can you learn?
* Mechanism of action of GSK 3 inhibitors
* Explore in vivo activity involved & analyse future prospects
Dr. Daniella Zheleva
Head, Protein Biochemistry & Programme Leader
Cyclacel

12:00 CASE STUDY: Glimepiride and latest novel findings
* Discover Sanofi-Aventis' strategies in diabetic research
* Novel therapeutic targets and findings
- Cross-talk to the insulin signalling cascade
* Understand Glimepiride: Beyond insulin secretion
- novel preclinical & clinical findings
* Activation of "anti-diabetic" kinases: how to overcome
this challenge? New ideas and methods
Professor Günter Müller
Section Head Biochemistry,TD Metabolism
Sanofi-Aventis

12:40 Lunch

14:00 CASE STUDY: Advances in point of care testing for
the management of diabetes
* Current evidence on self monitoring of blood glucose
* New technologies for self monitoring of blood glucose
* Value of telemedicine patient support systems in the
management of diabetes
* Devolution of diabetes management to the primary
care sector
* Role of diagnostics in diabetes management: the future
Professor Chris Price
Vice President, Outcomes Research
Bayer

OVERCOMING CHALLENGES IN INSULIN RESISTANCE

14:40 CASE STUDY: Ingenium's approach to insulin
resistance
* Overview of type II Diabetes market & current therapies
* Current therapies alleviating insulin resistance
* Analyse ongoing research studies into insulin resistance
* What mediates insulin resistance? - Understanding the
contribution of membrane lipids
* Evaluate membrane composition & lipotoxicity in obesity
* Examine animal model with altered insulin sensitivity
Dr. Klaus Dembowsky
Vice President, Drug Discovery
Ingenium Pharmaceuticals

15:20 Afternoon Tea

15:40 CASE STUDY: Novel concept idea - antidiabetic
agents with cardioprotective mechanisms
* Is cardioprotection an unmet clinical need in the
treatment of diabetes? Understanding the complication
* What are the effects of current antidiabetic treatments
on cardiovascular risk?
* What may be the effect on newly emerging antidiabetic
treatments on cardiovascular risk
* Explore future perspectives & discover opportunities
Dr. Richard Carr
Vice President, New Antidiabetic Agents
Novo Nordisk

16:20 CASE STUDY: Understanding the islet & new
therapeutic approaches: The incretin, glucagonostatic
& insulinotropic effects
* Amylin the hormone and amylinomimetics
* Examine GLP-1 and incretin mimetics
* Promising approaches to Type 1 therapy
* Treatment of the Type 2 patient
* Entry into the market with new peptide therapies
Dr. David Maggs
Senior Director, Medical Affairs
Amylin

17:00 CASE STUDY: Incretin mimetics: The next step in
treating type 2 diabetes
* Understanding GLP-1 physiology and the therapeutic
concept of incretin mimetics: analyse current findings
* Lilly's novel therapy under development for type 2
* Exenatide:Mode of action & pre-clinical trials results
* Promising results so far - from phase III clinical trials
* Identify where opportunities lie in the market
Dr. Andreas Festa
Medical Advisor
Eli Lilly

17:40 Questions and Summation from conference chair


DAY TWO THURSDAY 24TH MARCH 2005

Conference Chair Day Two
Dr. Jacques Mizrahi
Global Therapy Area Head, Vascular and Metabolic Diseases
Roche

09:00 Registration and coffee

09:30 Opening remarks from the chair

09:40 Stem cell engineering in diabetes
* Discover transcriptional regulation of critical beta-cell
genes and cell signaling events
* Examine PDX-1 gene, insulin gene and the IAPP gene
* ß-cell replacement therapies - A new light for the future?
* Muscle-targeted gene therapy for treatment of diabetes
* Understand stem cell engineering in diabetes therapies
- Post-HFEA license studies
- What can you implement in your R&D?
Dr. Wendy MacFarlane
Lecturer
University of Newcastle upon Tyne

EXPLORE NEW SCIENCE IN TREATMENT & INSULIN DELIVERY

10:20 CASE STUDY: Understanding erectile dysfunction in
diabetes
* Overview of ED in diabetes and global prevalence
* Examine possible pathogenesis and therapeutic targets
- Where opportunities lie ahead
* What are the current available therapeutic options?
* Future prospective of strategy to conquer ED in diabetes
- Potential avenues for future research
Dr. Nandan Koppiker
Director
Pfizer

11:00 Morning Coffee

11:20 CASE STUDY: Advancement in insulin delivery system
* The importance of insulin in the treatment of diabetes
* Overview of current treatment & medical devices in diabetes
* Altea's Basal Insulin delivery system - What's new?
* AT-1391 non-invasive insulin using PassPort system
- Mechanism of action
- Efficacy results
* Future approaches in pipeline development
Dr. Stefan Arver
Vice President, Europe
Altea Therapeutics

12:00 CASE STUDY: Simplified prandial insulin delivery
* Current insulin delivery methods - Global unmet needs
* Novel rapid mist buccal delivery via handheld device
* Discover the advantages of this unique liquid aerosol
formulation - What can you implement?
* Metered dosage of insulin and rapid absorption
* Promising clinical results in type 1 diabetic patients
* Promising clinical results in type 2 diabetic patients
Dr. Gerald Berstein
Vice President, Medical Affairs
Generex Biotechnology

12:40 Lunch

14:00 CASE STUDY: Overcoming challenges in oral delivery
of Insulin
* Importance of insulin in diabetes treatment
* Understand the correlation between efficacy and method of
administration
* Current R&D studies of oral insulin therapies - Pros & Cons
- Advantages of portal-hepatic route of absorption
- Increased patient compliance rate
* Emisphere's participation in oral insulin R&D
- Discover future prospects and pinpoint opportunities
Dr. Ehud Arbit
Vice President, Medical Research
Emisphere Technologies

STRATEGIES IN METABOLIC SYNDROME THERAPIES

14:40 A perspective on current anti-obesity strategies
* Prevalence of obesity and it's associated risks
* Current treatments to combat obesity: sibutramine &
rimonabant - Increasing energy expenditure
* How effective are current OTC anti-obesity products?
* Comparative study of safety issues -current & past treatments
* Beneficial values of FDA-approved long term treatments
Dr. John Clapham
Department of Molecular Pharmacology
AstraZeneca

15:20 Afternoon Tea

15:40 CASE STUDY: Insulin sensitizing: A better way
through anti-obesity drugs?
* Prevalence studies on obesity and global unmet needs
* Current anti-obesity therapies and therapeutic targets
* Anti-obesity drugs: Mechanism of action
- Insulin sensitizing - Pros and Cons
* How will this novel concept affect the disease outcome?
* Discover how you can implement into your R&D
Dr. Jacques Mizrahi
Global Therapy Area Head, Vascular and Metabolic Diseases
Roche

16:20 CASE STUDY: Metabolic syndrome: Acetyl-CoA
carboxylase inhibition
* The definition and prevalence of metabolic syndrome
* What are the current therapeutic targets in metabolic
syndrome research?
* Analyse novel concept - ACC inhibition: mechanism of action
of CP-640186 - Efficacious results so far
* Overcoming developmental challenges
Dr. H. James Harwood
Principle Research Investigator,
Cardiovascular & Metabolic Diseases
Pfizer

17:00 Questions and Discussion

17:20 Summation of Conference from chairman

17:30 Close of Conference











Terms & Conditions
NB - Due to high demand, we do not 'reserve' or 'hold' places - a request
for an invoice to be raised will be treated as an official booking and will
be subject to the cancellation policy as outlined below.
Cancellations/substitutions and name changes: All bookings carry a 50%
liability after the booking has been made, by post fax, email or web. There
will be no refunds for cancellations received on or after one month before
the start of the conference (e.g. cancellation on or after 20th January for
a conference starting on 20th February). If you decide to cancel after this
date the full invoice remains payable. Conference notes, which are available
on the day, will be sent to you. Unfortunately we are not able to transfer
places between conferences and executive briefings. However if you are
unable to attend the event you may make a substitution/name change at any
time as long as we are informed in writing by e-mail, fax or post. Name
changes and substitutions must be from the same company and are not
transferable between companies or countries.

Indemnity: visiongain Ltd reserve the right to change the
conference/executive briefing content, timing, speakers or venue without
notice. The event may be postponed or cancelled due to acts of terrorism,
war, extreme weather conditions, industrial action, acts of God or any event
beyond the control of visiongain Ltd. If such a situation arises we will
endeavour to reschedule the event. However, visiongain Ltd cannot be held
responsible for any cost, damage or expenses, which may be incurred by the
customer as a consequence of the event being postponed or cancelled. We
therefore strongly advise all customers to take out insurance to cover the
cost of the registration, travel and expenses.

To unsubscribe please reply with unsubscribe in the subject line.

Data protection: Visiongain Ltd gathers and manages data in accordance with
the Data Protection Act 1998. Information contained about you may be used to
update you on visiongain Ltd products and services via post, telephone, fax
or email, unless you state otherwise. If you wish your details to be
amended, please send your request to the Database Manager, visiongain Ltd,
40 Tooting High Street, London, SW17 0RG. Alternatively please reply with
unsubscribe in the subject line. Please allow approximately 7 days for your
removal or update request, you may receive additional pieces of
communication from visiongain Ltd during the transitional period, whilst the
changes come into effect.

---